- About ELS
- Therapeutic Areas
- Operational Metrics
- Contact Us
The science of dermatology in India has evolved over the last 20 years from a specialty practice to a mainstream commercial practice with over 10,000 practitioners throughout the country. India, with a population of over 1.25 billion, is an ideal location for conducting clinical research in dermatology. One of every twenty people and 20-30% of cases in pediatric practice have dermatological issues. Many patients are treatment naïve and non-transient.
India therefore is an ideal location for conducting clinical research in dermatology. Most prevalent skin diseases include pediculosis, tinea, vitiligo, pityriasis versicolor, pityriasis, alba, dermatitis, urticaria, impetigo, scabies and boils.
Fungal infections of the skin are seen in 28% patients with a higher prevalence among males. Tinea corporis accounts for 78% of the superficial fungal infections. The prevalence of pediculosis among school children varies from 17% in one study, to 56% in another. Eczema and skin allergies account for nearly 30% of the cases as accounted by pediatric dermatologists in India. Acne has affected nearly 51% of boys and 38% of girls in the age group 12-17 years.
Excel Life Sciences (ELS) has significant experience in running and supporting clinical trials for dermatology in India. In fact, ELS has one of the largest networks of investigative sites and investigators in India, including some of the country’s leading Dermatology investigators and centers.
Using sophisticated databases of detailed site information, demographics and epidemiology data we can quickly determine if India is the right fit for your study. In addition, ELS can quickly mobilize a team of experienced project managers to conduct a study feasibility analysis and determine the appropriate sites and availability of patients. We have significant experience in the area of dermatology and we are confident that we can assist you with your next study.